Everyone Deserves Access to Innovation
Our Mission
At ICE Biopharma, our mission guides us. Medical innovation delivered by the healthcare industry means our lives are longer and our quality of life better.
Yet access to innovation is constrained, especially for people suffering from diseases with a high unmet need. The reasons for this lack of access are multifactorial: economic, regulatory and political.
At ICE Biopharma we aim to be part of the solution. By creating a new ecosystem of partnering and collaboration, we want to augment the number of new medicines reaching the hands of patients who will benefit from them.
Because 'Everyone deserves access to innovation'.
ICE Biopharma: Two Core Businesses
In-Licensing & Commercialization
Product Commercialization in Europe, Canada, MENA
Biotech / ICE Biopharma / Investors
Upfronts / Milestones / Royalties
Consultancy
International Operators for Biotech Operators
Cross-Functional Experts in Key Disciplines
Proven Track Record
Our Advisory and Partnering Approach
Consulting and Executing
Biotechs want to launch their products in Europe and Canada. However, this step is very costly and requires regional expertise to succeed. ICE Biopharma advises and executes commercial strategies for companies wishing to launch specialty, hospital, and orphan/rare products in Europe and Canada, executing on our and our partners’ mission to deliver innovation to patients.
A tailored model - Commercial Partner of Choice
We will co-create European & Canadian regulatory strategy. We will negotiate favorable access and reimbursement terms. We will deploy rightsized customer-facing teams for each asset in the major European markets & in Canada, leveraging centralized support functions across our in-licensed product portfolio. We are an International Commercial Engine.
ICE Biopharma Founders
Francis Marsland, CLO
Sebastian Stachowiak, CEO
Sebastian Stachowiak, CEO
- Over 25 years experience working in pharma and biotech
- Last role: VP, Head of Legal & Compliance, Europe & Middle East for GBT
- Previous Role: Chief Administrative Officer at Vicarius Pharma
- Passionate about securing great outcomes on fair terms
Sebastian Stachowiak, CEO
Sebastian Stachowiak, CEO
Sebastian Stachowiak, CEO
- Over 20 years experience working in large pharma and biotechs
- Last role: Head of Europe & Middle East for Global Blood Therapeutics (GBT)
- Previous Role: VP Commercial Operations International for TESARO
- Passionate about supporting children with debilitating conditions
Boris Javelle, CFO
Sebastian Stachowiak, CEO
Boris Javelle, CFO
- Over 20 years experience working in large pharma and biotechs
- Last role: Encentrio Group CFO - closed Series A financing
- Previous Role: SVP Head of Europe Nektar Therapeutics
- Passionate about finding innovative solutions to business challenges
A Passionate And Experienced Team of Subject-Matter Experts
About Us
A Powerful and Experienced Leadership Team
A Network of pan-European & Canadian Experts
A Network of pan-European & Canadian Experts
70 Years Experience of launching innovative products in Europe & Canada, Supply Chain
Over 1500 Employees hired
$50m Successfully raised in Series A Funding
$1b Direct revenue responsibility
$25b Biotech Buyout Value
A Network of pan-European & Canadian Experts
A Network of pan-European & Canadian Experts
A Network of pan-European & Canadian Experts
We are connected with leading, medical, regulatory, market access and commercial leaders across Europe & Canada, and across multiple therapeutic areas. We will put the best talent behind our partners' assets.
A commitment to Innovation
A Network of pan-European & Canadian Experts
A commitment to Innovation
We are determined to secure equitable access to innovative therapeutics for European & Canadian patients on terms that appropriately reward the innovators